Author(s): Millar AW, Lynch KP
Abstract Share this page
Abstract The failure of many cytostatic agents in Phase III clinical trials for treatment of common cancers has led researchers to question current approaches to trial development. Recent studies offer some clues as to what is wrong with two particular aspects of clinical trial design--survival as an end point and simultaneous combination with cytotoxic chemotherapy--and indicate possible alternatives.
This article was published in Nat Rev Cancer
and referenced in Advances in Pharmacoepidemiology and Drug Safety